Onasemnogene abeparvovec-xioiMeSH concept

https://ansm.sante.fr/tableau-marr/onasemnogene-abeparvovec
2024
false
false
false
France
French
guidelines for drug use
risk management
Zolgensma
onasemnogene abeparvovec
infusions, intravenous
patients guideline
child
spinal muscular atrophies of childhood
onasemnogene abeparvovec-xioi
biological products
recombinant fusion proteins

---
https://www.has-sante.fr/jcms/p_3442932/fr/zolgensma-onasemnogene-abeparvovec-amyotrophie-spinale
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
onasemnogene abeparvovec-xioi
onasemnogene abeparvovec
5q spinal muscular atrophy
gene therapy
infusions, intravenous
evaluation of the transparency committee
spinal muscular atrophies of childhood
Zolgensma

---
https://ansm.sante.fr/informations-de-securite/zolgensma-onasemnogene-abeparvovec-cas-dinsuffisance-hepatique-aigue-dissue-fatale
2023
false
false
false
France
French
pharmacovigilance note
risk
onasemnogene abeparvovec-xioi
Onasemnogene Abeparvovec
onasemnogene abeparvovec
liver function tests
continuity of patient care
Monitoring of liver function (regime/therapy)
liver failure, acute
child
infant
liver failure, acute
guidelines for drug use

---
https://recalls-rappels.canada.ca/fr/avis-rappel/zolgensma-onasemnogene-abeparvovec-et-cas-mortels-insuffisance-hepatique-aigue
2022
false
false
false
Canada
French
English
pharmacovigilance note
liver failure, acute
onasemnogene abeparvovec-xioi
guidelines for drug use
onasemnogene abeparvovec
drug monitoring
continuity of patient care
liver function tests
glucocorticoids
Chemical and Drug Induced Liver Injury
5q spinal muscular atrophy
spinal muscular atrophies of childhood

---